Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Keros Therapeutics Inc (KROS)

58.62   3.37 (6.1%) 03-07 03:37
Open: 56.65 Pre. Close: 55.25
High: 58.86 Low: 51.485
Volume: 108,928 Market Cap: 1,359M
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 58.911 - 59.326 59.326 - 59.649
Low: 50.795 - 51.189 51.189 - 51.495
Close: 58.044 - 58.727 58.727 - 59.257

Technical analysis

as of: 2021-03-05 5:10:07 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 77.82     One year: 88.76
Support: Support1: 51.49    Support2: 42.84
Resistance: Resistance1: 66.63    Resistance2: 75.99
Pivot: 61.96
Moving Average: MA(5): 58.15     MA(20): 63.38
MA(100): 65.50     MA(250):
MACD: MACD(12,26): -2.09     Signal(9): -1.48
Stochastic oscillator: %K(14,3): 20.95     %D(3): 13.46
RSI: RSI(14): 42.84
52-week: High: 88.80  Low: 20.10  Change(%): 191.9
Average Vol(K): 3-Month: 15279  10-Days: 10313

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
KROS has closed above bottom band by 25.8%. Bollinger Bands are 17.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 05 Mar 2021
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference - GlobeNewswire

Tue, 02 Mar 2021
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference - Yahoo Finance

Wed, 17 Feb 2021
Feb 17, 2021 - Piper Jaffray & Co. Buys Shattuck Labs Inc, Aytu BioScience Inc, Eaton Vance Corp, Sells Sempra Energy, Brookfield Infrastructure Corp, Keros Therapeutics Inc -

Wed, 17 Feb 2021
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - Yahoo Finance

Fri, 22 Jan 2021
Keros Therapeutics: Very Expensive For A Company Still In Early Stages Of Development - Seeking Alpha

Mon, 21 Dec 2020
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index - GlobeNewswire

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency n/a
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 23
Shares Float (M) 8
% Held by Insiders 14.90
% Held by Institutions 77.63
Shares Short (K) 632
Shares Short P. Month (K) 464

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin -1443.76
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) -0.318
Sales Per Share 0.108
EBITDA (p.s.) -1.546
Qtrly Earnings Growth
Operating Cash Flow (M) -34
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 543.52
Price to Cash Flow -39.50

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.